Positive News Sentiment NASDAQ:VNDA Vanda Pharmaceuticals - VNDA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.61 -0.04 (-0.52%) (As of 01/30/2023 03:49 PM ET) Add Compare Share Share Today's Range$7.51▼$7.6450-Day Range$6.87▼$10.9652-Week Range$6.73▼$15.23Volume172,124 shsAverage Volume530,817 shsMarket Capitalization$430.65 millionP/E Ratio63.42Dividend YieldN/APrice Target$12.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Vanda Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside58.5% Upside$12.00 Price TargetShort InterestHealthy3.55% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment1.62Based on 2 Articles This WeekInsider TradingSelling Shares$612,966 Sold Last QuarterProj. Earnings Growth860.00%From $0.05 to $0.48 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.99 out of 5 starsMedical Sector13th out of 1,049 stocksPharmaceutical Preparations Industry6th out of 514 stocks 3.0 Analyst's Opinion Consensus RatingVanda Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Vanda Pharmaceuticals has a forecasted upside of 58.5% from its current price of $7.57.Amount of Analyst CoverageVanda Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.55% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 0.52%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Vanda Pharmaceuticals is -1.77. Previous Next 3.7 News and Social Media Coverage News SentimentVanda Pharmaceuticals has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vanda Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $612,966.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions97.22% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to grow by 860.00% in the coming year, from $0.05 to $0.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is 63.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is 63.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 108.71.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vanda Pharmaceuticals (NASDAQ:VNDA) StockVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Read More Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Stock News HeadlinesJanuary 12, 2023 | finance.yahoo.comAre Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?January 6, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare ConferenceJanuary 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 19, 2022 | markets.businessinsider.comVanda Pharma: Phase III Study Shows Potential Of Fanapt In Treating Bipolar I DisorderDecember 16, 2022 | finance.yahoo.comVanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launchDecember 14, 2022 | finance.yahoo.comVanda Pharmaceuticals gets bad news in generic competition court rulingDecember 13, 2022 | marketwatch.comVanda Pharmaceuticals Shares Tumble After Loss in Hetlioz Patent Suit >VNDADecember 13, 2022 | finance.yahoo.comVanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA LitigationJanuary 30, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." December 5, 2022 | finance.yahoo.comVanda Pharmaceuticals is testing a drug for performance anxiety. It just got good news.December 2, 2022 | seekingalpha.comVanda says performance anxiety drug lowered stress in Phase 2 enrolleesDecember 2, 2022 | finance.yahoo.comVanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance AnxietyNovember 9, 2022 | finance.yahoo.comVanda Pharmaceuticals Third Quarter 2022 Earnings: Misses ExpectationsNovember 9, 2022 | finance.yahoo.comVanda Pharmaceuticals Announces Participation at November 2022 Investor ConferencesNovember 4, 2022 | finance.yahoo.comVanda Pharmaceuticals is spending big on R&D. Here’s what it has on tap for 2023.November 2, 2022 | finance.yahoo.comVanda Pharmaceuticals Reports Third Quarter 2022 Financial ResultsNovember 2, 2022 | finance.yahoo.comVanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue EstimatesOctober 26, 2022 | finance.yahoo.comVanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022October 20, 2022 | finance.yahoo.comShould Value Investors Buy Dynavax Technologies (DVAX) Stock?October 18, 2022 | nasdaq.comCalculating The Intrinsic Value Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)October 18, 2022 | finance.yahoo.comEstimating The Fair Value Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)October 11, 2022 | finance.yahoo.comShould Value Investors Buy Exelixis (EXEL) Stock?September 29, 2022 | finance.yahoo.comVanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide TherapeuticsSeptember 9, 2022 | marketwatch.comVANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ(R) IN JET LAG DISORDERSeptember 4, 2022 | finance.yahoo.comShareholders in Vanda Pharmaceuticals (NASDAQ:VNDA) are in the red if they invested five years agoAugust 31, 2022 | nasdaq.comDo Its Financials Have Any Role To Play In Driving Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Stock Up Recently?August 10, 2022 | msn.comLooking Into Vanda Pharmaceuticals's Return On Capital EmployedSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Company Calendar Last Earnings11/02/2022Today1/30/2023Next Earnings (Estimated)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VNDA CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees278Year Founded2002Price Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+57.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.12 Trailing P/E Ratio63.42 Forward P/E Ratio152.20 P/E GrowthN/ANet Income$33.15 million Net Margins2.52% Pretax Margin3.99% Return on Equity1.28% Return on Assets1.07% Debt Debt-to-Equity RatioN/A Current Ratio5.47 Quick Ratio5.46 Sales & Book Value Annual Sales$268.68 million Price / Sales1.60 Cash Flow$0.67 per share Price / Cash Flow11.32 Book Value$9.06 per share Price / Book0.84Miscellaneous Outstanding Shares56,590,000Free Float52,629,000Market Cap$430.65 million OptionableOptionable Beta0.64 Social Links Key ExecutivesDr. Mihael H. Polymeropoulos M.D. (Age 63)Founder, Pres, CEO & Chairman of The Board Comp: $1.4MMr. Kevin Patrick Moran (Age 39)Sr. VP, CFO & Treasurer Comp: $615.51kMr. Timothy Williams (Age 47)Sr. VP, Gen. Counsel & Sec. Comp: $675.67kMr. Joakim Wijkstrom (Age 57)Sr. VP & Chief Marketing Officer Comp: $779.67kMr. Gunther Birznieks (Age 53)Sr. VP of Bus. Devel. Comp: $644.4kMr. Scott L. HowellChief People OfficerMs. Elizabeth Van EveryHead of Corp. AffairsMore ExecutivesKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXAVEO PharmaceuticalsNASDAQ:AVEORigel PharmaceuticalsNASDAQ:RIGLXOMANASDAQ:XOMAEmergent BioSolutionsNYSE:EBSView All CompetitorsInsiders & InstitutionsStrs OhioBought 7,900 shares on 1/26/2023Ownership: 0.095%Comerica BankSold 9,509 shares on 1/26/2023Ownership: 0.060%Ziegler Capital Management LLCSold 7,419 shares on 1/24/2023Ownership: 0.056%Allspring Global Investments Holdings LLCBought 39,918 shares on 1/23/2023Ownership: 0.410%Maryland State Retirement & Pension SystemBought 23,138 shares on 1/18/2023Ownership: 0.041%View All Insider TransactionsView All Institutional Transactions VNDA Stock - Frequently Asked Questions Should I buy or sell Vanda Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VNDA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VNDA, but not buy additional shares or sell existing shares. View VNDA analyst ratings or view top-rated stocks. What is Vanda Pharmaceuticals' stock price forecast for 2023? 1 Wall Street research analysts have issued 1 year price objectives for Vanda Pharmaceuticals' shares. Their VNDA share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next year. This suggests a possible upside of 56.9% from the stock's current price. View analysts price targets for VNDA or view top-rated stocks among Wall Street analysts. How have VNDA shares performed in 2023? Vanda Pharmaceuticals' stock was trading at $7.39 on January 1st, 2023. Since then, VNDA shares have increased by 3.5% and is now trading at $7.65. View the best growth stocks for 2023 here. When is Vanda Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our VNDA earnings forecast. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday, November, 2nd. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by $0.04. The biopharmaceutical company had revenue of $65.32 million for the quarter, compared to analysts' expectations of $71 million. Vanda Pharmaceuticals had a net margin of 2.52% and a trailing twelve-month return on equity of 1.28%. What guidance has Vanda Pharmaceuticals issued on next quarter's earnings? Vanda Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $240.00 million-$270.00 million, compared to the consensus revenue estimate of $273.80 million. What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO? 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX). What is Vanda Pharmaceuticals' stock symbol? Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA." Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (2.81%), Allspring Global Investments Holdings LLC (0.41%), Exchange Traded Concepts LLC (0.10%), Strs Ohio (0.09%), Yousif Capital Management LLC (0.06%) and Comerica Bank (0.06%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vanda Pharmaceuticals' stock price today? One share of VNDA stock can currently be purchased for approximately $7.65. How much money does Vanda Pharmaceuticals make? Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $432.91 million and generates $268.68 million in revenue each year. The biopharmaceutical company earns $33.15 million in net income (profit) each year or $0.12 on an earnings per share basis. How many employees does Vanda Pharmaceuticals have? The company employs 278 workers across the globe. How can I contact Vanda Pharmaceuticals? Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450. This page (NASDAQ:VNDA) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.